Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Income from Non-Controlling Interests (2022 - 2025)

Oramed Pharmaceuticals' Income from Non-Controlling Interests history spans 4 years, with the latest figure at -$1000.0 for Q4 2025.

  • For Q4 2025, Income from Non-Controlling Interests changed N/A year-over-year to -$1000.0; the TTM value through Dec 2025 reached -$58000.0, changed N/A, while the annual FY2025 figure was -$34000.0, 20.93% up from the prior year.
  • Income from Non-Controlling Interests reached -$1000.0 in Q4 2025 per ORMP's latest filing, up from -$6000.0 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $834000.0 in Q4 2023 to a low of -$587000.0 in Q4 2022.
  • Average Income from Non-Controlling Interests over 4 years is -$87714.3, with a median of -$45000.0 recorded in 2023.
  • Peak YoY movement for Income from Non-Controlling Interests: skyrocketed 242.08% in 2023, then plummeted 250.0% in 2025.
  • A 4-year view of Income from Non-Controlling Interests shows it stood at -$587000.0 in 2022, then surged by 242.08% to $834000.0 in 2023, then tumbled by 102.76% to -$23000.0 in 2024, then surged by 95.65% to -$1000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Income from Non-Controlling Interests are -$1000.0 (Q4 2025), -$6000.0 (Q3 2025), and -$28000.0 (Q2 2025).